-$0.46 EPS Expected for Intellia Therapeutics Inc (NTLA) This Quarter

Share on StockTwits

Wall Street brokerages expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.46) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.15). Intellia Therapeutics posted earnings of ($0.44) per share in the same quarter last year, which would suggest a negative year over year growth rate of 4.5%. The business is scheduled to issue its next quarterly earnings report on Tuesday, October 30th.

According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($1.56). For the next financial year, analysts forecast that the business will report earnings of ($2.52) per share, with EPS estimates ranging from ($3.15) to ($1.94). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. The business had revenue of $7.68 million during the quarter, compared to analyst estimates of $6.39 million. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The company’s quarterly revenue was up 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.45) EPS.

Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. BidaskClub downgraded shares of Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 26th. ValuEngine raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research report on Friday, May 18th. Finally, Chardan Capital raised shares of Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $34.14.

NASDAQ:NTLA traded up $0.64 during trading hours on Friday, hitting $28.13. 6,866 shares of the company were exchanged, compared to its average volume of 674,131. The company has a market cap of $1.22 billion, a PE ratio of -15.05 and a beta of 2.93. Intellia Therapeutics has a 52-week low of $15.06 and a 52-week high of $35.99.

In related news, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $25.04, for a total transaction of $167,417.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John M. Leonard sold 8,400 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The disclosure for this sale can be found here. Insiders have sold 28,458 shares of company stock worth $764,361 over the last three months. 12.80% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in shares of Intellia Therapeutics by 108.0% in the fourth quarter. Wells Fargo & Company MN now owns 34,767 shares of the company’s stock valued at $668,000 after buying an additional 18,050 shares during the last quarter. BlackRock Inc. raised its position in shares of Intellia Therapeutics by 1.9% in the fourth quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 42.5% in the fourth quarter. Geode Capital Management LLC now owns 195,925 shares of the company’s stock valued at $3,765,000 after buying an additional 58,411 shares during the last quarter. Deutsche Bank AG raised its position in shares of Intellia Therapeutics by 8.5% in the fourth quarter. Deutsche Bank AG now owns 41,744 shares of the company’s stock valued at $800,000 after buying an additional 3,279 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Intellia Therapeutics by 306.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 129,900 shares of the company’s stock valued at $2,497,000 after buying an additional 97,936 shares during the last quarter. Institutional investors own 59.81% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Article: Trading Strategy Methods and Types

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.